Related Experiment Video
Updated: Jul 13, 2025

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
[Splanchnic vein thrombosis]
A Riescher-Tuczkiewicz1, L Elkrief2, P-E Rautou3
1Université Paris-Cité, Inserm, centre de recherche sur l'inflammation, UMR 1149, Paris, France.
Insights
Splanchnic vein thrombosis, including Budd-Chiari syndrome and portal vein thrombosis, often stems from myeloproliferative neoplasms. Early diagnosis and anticoagulation are crucial for managing these rare conditions and preventing complications like portal hypertension.
Area of Science:
- Hepatology
- Vascular Medicine
- Hematology
Context:
- Splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis, both rare conditions.
- These thromboses can lead to portal hypertension and its severe complications.
- Myeloproliferative neoplasms are a primary risk factor for these conditions in the absence of liver disease.
Purpose:
- To review the causes, diagnosis, and management of splanchnic vein thrombosis.
- To highlight the importance of a comprehensive workup for thrombosis risk factors.
- To discuss the role of anticoagulation and transjugular intrahepatic portosystemic shunt in patient management.
Summary:
- Budd-Chiari syndrome and portal vein thrombosis share risk factors, notably myeloproliferative neoplasms.
- Portal vein thrombosis in cirrhosis patients indicates a poorer prognosis.
- Long-term anticoagulation is a mainstay treatment, with TIPS as a second-line option.
Impact:
- Improved understanding of the natural history of these rare diseases.
- Enhanced diagnostic strategies for identifying thrombosis risk factors.
- Optimized management protocols for splanchnic vein thrombosis, improving patient outcomes.
Abstract:
Splanchnic vein thrombosis includes Budd-Chiari syndrome and portal vein thrombosis. These diseases share common features: (i) they are rare diseases and (ii) they can lead to portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, the most common being myeloproliferative neoplasms. A rapid and comprehensive workup for thrombosis risk factors is necessary in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis, and is associated with a worse course of cirrhosis. Indications for anticoagulation in patients with cirrhosis are increasing. Transjugular intrahepatic portosystemic shunt is a second-line procedure in this setting. Because of the rarity of these diseases, high-level evidence studies are rare. However, collaborative studies have provided a better understanding of their natural history and allowed to improve the management of these patients. This review focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, patients with portal vein thrombosis without underlying liver disease, and patients with cirrhosis and portal vein thrombosis.
More Related Videos
06:44Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
Published on: April 13, 2018
04:00Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
Published on: November 15, 2024
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Esophageal Varices-I: Introduction
Venous Thrombosis III: Interprofessional Care
Varicose Veins I: Introduction
Veins of the Abdomen and Pelvis
The inferior vena cava is fed by numerous smaller veins. The lumbar veins, for instance, drain the posterior abdominal wall, emptying both directly into the inferior vena cava and into the...